TRAX First Tracks Biotherapeutics, Inc.

NEUTRAL Impact: 4/10 EFFECT
Horizon days Filed May 13, 2026 Processed 1mo ago SEC 9999999995-26-001596
IPO/offering going effective
Latest settled — T+5d
TRAX ▼ -9.60% at T+5d
NEUTRAL call ✗ call lost -9.60% · α vs SPY -8.45% · entry $18.43 → $16.66
Next anchor: T+20d due yesterday
Currently $17.64 · -4.29% from $18.43 entry
Entry anchored
May 12, 03:59 PM ET
via Databento tick
T+1d
-1.47%
call -1.47% · α -2.24%
$18.16
settled 4w ago
T+5d
-9.60%
call -9.60% · α -8.45%
$16.66
settled 24d ago
T+20d
call — · α —
due yesterday
T+60d
call — · α —
in 8w

Price Chart

Loading chart...

Executive Summary

First Tracks Biotherapeutics' S-1 registration (333-295719) became effective on May 12, 2026, covering the resale of up to 10,497,054 shares by selling stockholders. The company receives no proceeds from this offering, which stems from a March 2026 private placement that raised ~$80M at $13.81/share. The effectiveness creates a near-term overhang as the registered shares become freely tradable, though the company itself is not raising capital.

Actionable Insight

The effectiveness unlocks a large block of shares for secondary selling, creating near-term overhang. Monitor for any selling stockholder filings (Form 144) or volume spikes in the coming days. The company's cash position was recently boosted by the $80M private placement, so no immediate capital need — but the overhang may cap upside until the registered shares are absorbed.

Key Facts

  • S-1 registration effective May 12, 2026 (SEC File No. 333-295719)
  • Covers resale of up to 10,497,054 shares by selling stockholders
  • Company receives no proceeds from this offering
  • Shares stem from March 2026 private placement at $13.81/share raising ~$80M for the company
  • Effectiveness date: May 12, 2026; filing accepted May 13, 2026

Financial Impact

Up to 10.5M shares become eligible for resale, representing ~16.9% of current shares outstanding (based on ~62M shares at $621M market cap / ~$10 stock price). No new capital raised by the company.

dilutionshare overhang

Risk Factors

  • Near-term selling pressure from registered shares entering the market
  • Potential price suppression until the overhang clears
  • No company proceeds from this offering — dilution without capital benefit

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001596
Document: 9999999995-26-001596-index.html9999999995-26-001596
Document: 9999999995-26-001596.txt9999999995-26-001596
11 reports for TRAX
Performance horizon
Filters
Rows
Reports for TRAX — sortable, filterable
Type Now
May 14, 2026
29d ago
8-K
NEUTRAL ★ 4/10
$16.90 $17.18▲ +1.66%▲ +0.69%$17.64 (+4.38%)
May 13, 2026
4w ago
EFFECT
NEUTRAL ★ 4/10
$18.43 $16.66▼ −9.60%▼ −8.45%$17.64 (−4.29%)
May 8, 2026
5w ago
S-1
NEUTRAL ★ 2/10
$18.76 $17.79▼ −5.17%▼ −5.09%$17.64 (−5.97%)
Apr 1, 2026
10w ago
3
NEUTRAL ★ 2/10
awaiting T+5
Apr 1, 2026
10w ago
3
NEUTRAL ★ 3/10
awaiting T+5
Apr 1, 2026
10w ago
3
NEUTRAL ★ 2/10
awaiting T+5
Apr 1, 2026
10w ago
3
NEUTRAL ★ 2/10
awaiting T+5
Apr 1, 2026
10w ago
3
NEUTRAL ★ 3/10
awaiting T+5
Apr 1, 2026
10w ago
3
NEUTRAL ★ 3/10
awaiting T+5
Apr 1, 2026
10w ago
3
NEUTRAL ★ 2/10
awaiting T+5
Showing 10 of 11

US Market Status

Market Closed — Opens Mon (49h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access